Drug intelligence / Profile preview

Salvinorin A

Development stage
Phase 2
Modality
Small Molecules
Administration
Inhalation, Buccal, Oral
01

Overview

Salvinorin A is a naturally occurring trans-neoclerodane diterpenoid and the principal psychoactive compound found in the plant Salvia divinorum. It is unique among hallucinogens as it is not an alkaloid and lacks a basic nitrogen atom. Salvinorin A acts as a highly potent and selective agonist of the kappa opioid receptor (KOR), with activity at doses as low as 200 micrograms. Unlike classical psychedelics, it does not act on serotonin 5-HT2A receptors but has been shown to have some effect on dopamine D2 receptor (partial agonist) and cannabinoid CB1 receptor. Its effects are characterized by intense but short-lived hallucinations, dissociation, sedation, dysphoria, and alterations in perception. Due to rapid metabolism—primarily hydrolysis to inactive salvinorin B—and poor oral bioavailability, its psychoactive effects are brief when administered via non-oral routes such as smoking or buccal absorption. Research has explored potential therapeutic applications for salvinorin A in neuropsychiatric disorders (such as depression), addiction treatment, acute brain injury (including ischemic stroke), and neuroprotection due to its ability to modulate abnormal neuronal activity patterns[1][3][5][6].

Other names
SalvinorinSA
02

Targets

KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on Salvinorin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salvinorin A.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call